Advaxis (ADXS) has risen sharply, recording gains of 74.75% in the past 4 weeks. However, the stock has corrected -3.39% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 74.08% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
Advaxis, Inc. is up 72.54% in the last 3-month period. Year-to-Date the stock performance stands at 36.18%. The stock has recorded a 20-day Moving Average of 14.52% and the 50-Day Moving Average is 41.16%.
Advaxis (NASDAQ:ADXS): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $13.94 and $13.59 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $14.10. The buying momentum continued till the end and the stock did not give up its gains. It closed at $13.70, notching a gain of 1.18% for the day. The total traded volume was 840,865 . The stock had closed at $13.54 on the previous day.
Also, Equity Analysts at the Barclays maintains the rating on Advaxis (NASDAQ:ADXS). The brokerage firm has issued a Overweight rating on the shares. The Analysts at the ratings agency raises the price target from $15 per share to $20 per share. The rating by the firm was issued on August 3, 2016.
Advaxis, Inc. is a United States-based clinical-stage biotechnology company. The Company is focused on developing various cancer immunotherapies that use the bodys natural immune system to redirect the immune response to kill cancer. Its Lm Technology is a cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen, and neutralizes regulatory T cells and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Its Lm Technology immunotherapy, axalimogene filolisbac (ADXS-HPV), targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase II in invasive cervical cancer, Phase I/II in head and neck cancer, and Phase I/II in anal cancer. It has preclinical program with immunotherapies in development for cancers and infectious diseases.